Unicycive Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Unicycive Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2021 to Q2 2024.
  • Unicycive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $641K, a 345% increase year-over-year.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.77M, a 68.8% increase from 2022.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.05M, a 8.39% increase from 2021.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $966K, a 316% increase from 2020.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $641K +$497K +345% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $522K +$378K +263% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q2 2023 $144K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $144K -$146K -50.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q1 2022 $290K +$88K +43.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-16
Q1 2021 $202K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.